Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ROS1-selective inhibitor NVL-520

/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,American ,Joshua Horan ,Jessicaj Lin ,Nuvalent Inc ,Twitter ,Cancer Center ,Professor Of Medicine At Harvard Medical School ,Nasdaq ,Exchange Commission ,American Association For Cancer Research ,Company Quarterly Report On Form ,Cancer Discovery ,American Association ,Cancer Research ,Thoracic Oncologist ,Mass General Cancer Center ,Assistant Professor ,Harvard Medical School ,Vice President ,Private Securities Litigation Reform Act ,Quarterly Report ,Nuvalent ,Nc ,